Latest news with #AbbottLaboratories
Yahoo
10 hours ago
- Business
- Yahoo
[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach around USD 2,943.92 Million by 2034, at a CAGR of 16.65% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Artivion Inc., Athersys Inc., Baxter International Inc., Cellular Logistics Inc., Elutia Inc., Heartseed Inc., Medtronic Plc, Merck kGaA, Mesoblast Ltd., Neoolife Inc., Tejiin Limited, Terumo Corporation, and W.L. Gore & Associates, Inc and others. Austin, TX, USA, July 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Cardiac Tissue Engineering Market Size, Trends and Insights By Material (Scaffold, Stem Cells), By Product (Heart Valve, Vascular Grafts), By Application (MI, Congenital Heart Disease), By Distribution Channel (Hospitals & Clinics, Academics & Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Cardiac Tissue Engineering Market size & share was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach a value of around USD 2,943.92 Million by 2034, at a compound annual growth rate (CAGR) of about 16.65% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Overview According to industry experts at CMI, the implementation of new strategies and technologies by manufacturers presents lucrative opportunities for players in the Cardiac Tissue Engineering Market during the forecast period. Furthermore, the growing significance of organized retailing is expected to drive the future growth of the market. Key Trends & Drivers Integration of 3D Bioprinting in Cardiac Tissue Fabrication: 3D bioprinting has reshaped the cardiac tissue engineering market as it enables the precise fabrication of the heart tissue using the layer by layer deposition of the bioinks containing cells and biomaterials. This enables the development of customized cardiac grafts with anatomy that closely corresponds to native tissue architecture and function. Bioprinted cardiac patches and vascular networks demonstrate superior cell viability, integration with tissues, and scalability. Along with improvement in printing methods, this allows for mass production of grafts that are tailor-made for specific patients, hence minimizing the use of donor tissue. This trend is gathering pace in both research and clinical spheres, whereby it fosters innovation at the forefront of regenerative cardiovascular interventions. Advances in Stem Cell and iPSC Technology: The development of the Induced Pluripotent Stem Cell (iPSC) Technology along with the fine-tuning is expected to boost the growth of the cardiac tissue engineering market. iPSCs provide an ethically acceptable cardiomyocyte and vascular cell source from among the variety of patients for engineered tissues. Their resemblance to natural development and responsiveness to external stimuli being suitable traits for regeneration applications further add to their idealness. The ongoing research is enhancing reprogramming and differentiation protocol efficiency as well as augmenting the maturity and functionality of cardiac cells. Thus, such innovations even help in reducing immune rejection and conform to patient-oriented therapies, making stem cell technology one of the weighing stones in the turn toward cardiac tissue engineering solutions. Rising Utilization of Smart Scaffolds and Bioactive Scaffolds: Smart scaffolds that respond to physiological stimuli for the release of bioactive molecules into the cardiac tissue engineering field are transforming its scope. These advanced scaffolds provide structural support to the cells but also aid in their attachment, proliferation, and differentiation by mimicking the extracellular matrix of the heart. Nanotechnology and material science innovations are ensuring scaffolds with better conductivity, biodegradability, and mechanical properties. Bioactive scaffolds with growth factors or signalling peptides further augment tissue regeneration. The use of such intelligent materials in enhancing the therapeutic efficacy is a major trend leading to the development of the next-generation functional implantable cardiac constructs. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ Rise of Regenerative Cardiology for Pediatric Care Applications: This burgeoning need for regenerative solutions in pediatric cardiology is one of the main prevailing trends in cardiac tissue engineering space. Children afflicted with congenital heart defects require multiple surgeries because synthetic grafts and valves do not grow with the body. Tissue-engineered heart valves and patches, produced with heart cells derived from autologous cells, offer the possibility of growth, remodeling, and natural integration within the child's cardiovascular system. This advancement reduces the frequency of repeated interventions and improves long-term outcomes. Fueled by heightened research focus and enabled by regulatory pathways for pediatric therapies, this trend is accelerating the clinical translation of engineered solutions in pediatric cardiac care. Expansion of Clinical Trials and Translational Research: The surge in the clinical trials along with the translational research provides progress in the cardio tissue engineering solutions from lab-to-bedside. The academic institutions along with the startups and pharmaceutical companies are investing in the phase I/II trials for the safety and efficacy evaluations of the engineered heart tissue along with patches and valves. These trials are required for regulatory approvals and commercialization strategies. Collaboration between research centers and hospitals is ongoing to aid trial design and patient recruitment. This trend reflects renewed confidence in regenerative cardiac therapies and is a prerequisite for building clinical evidence, which then attracts funding and accelerates broader acceptance of the technology in the market. Personalized and Precision Cardiac Regeneration Therapies: The personalized medicines are transforming cardiac tissue engineering as they enable treatments based on the patient's genetic and physiological profiles. In this way, better understanding is achieved of the causes and mechanisms of diseases by means of the number of genomics, proteomics, and data analytic techniques, which direct the manufacturing of cardiac constructs with cells cultured from patients. Thus, these therapies stand against immune rejection on the physician's side, and they also keep the compatibility and healing of the patient in consideration. Precision methods like CRISPR are also being evaluated as options to target genetic mutations ahead of tissue engineering applications. Patient-specific approaches to healing are further improving treatment, strengthening cardiac functionality for the long run, and embracing wider trends within precision healthcare, in alignment with thereby sustaining the growth of the market. Report Scope Feature of the Report Details Market Size in 2025 USD 735.98 Million Projected Market Size in 2034 USD 2,943.92 Million Market Size in 2024 USD 632.10 Million CAGR Growth Rate 16.65% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Material, Product, Application, Distribution Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Cardiac Tissue Engineering report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Cardiac Tissue Engineering report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ SWOT Analysis Strengths: Cardiovascular diseases (CVDs) are the leading cause of death globally. Heart failure, often resulting from myocardial infarction (heart attack) and the limited regenerative capacity of the adult heart, represents a significant clinical challenge. The increasing incidence of CVDs globally, driven by aging populations, lifestyle factors, and comorbidities like diabetes and obesity, ensures a continuously expanding patient pool requiring advanced treatments. Weakness: The development of cardiac tissue engineering therapies involves extensive, complex, and costly research & development phases. Replicating the intricate, anisotropic structure, electrical conductivity, synchronized contraction, and robust vascularization of native human heart tissue is extremely challenging. Ensuring adequate vascularization (blood supply) within thick engineered cardiac tissues is critical for their survival and function in vivo. Opportunities: The demographic shift towards an older population, coupled with the rising global burden of cardiovascular diseases, ensures a growing demand for advanced cardiac therapies. Continued progress in induced pluripotent stem cells (iPSCs) and other stem cell sources for generating cardiomyocytes offers more patient-specific and less immunogenic cell sources for tissue engineering. Continued government funding for regenerative medicine and rising healthcare expenditure, particularly in developed nations, will fuel market growth. Threats: The high risk associated with clinical trials for novel therapies means that any major setback or failure could severely damage market confidence and delay progress. The use of stem cells and the creation of 'living' tissues raise ethical considerations that could impact public acceptance and regulatory frameworks. The highly innovative nature of the market could lead to complex intellectual property disputes among research institutions and companies. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ Key questions answered in this report: What is the size of the Cardiac Tissue Engineering market and what is its expected growth rate? What are the primary driving factors that push the Cardiac Tissue Engineering market forward? What are the Cardiac Tissue Engineering Industry's top companies? What are the different categories that the Cardiac Tissue Engineering Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Cardiac Tissue Engineering market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Cardiac Tissue Engineering Research Report | Fast Delivery Available - [220+ Pages] @ Regional Analysis The Cardiac Tissue Engineering Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region: North America: North America dominates the cardiac tissue engineering market due to advanced healthcare infrastructure, robust R&D investments, and a high prevalence of cardiovascular diseases. Strong support from government bodies, leading academic institutions, and a concentration of biotech firms fuel innovation in regenerative therapies. The United States holds the largest share of the cardiac tissue engineering market in North America, driven by a well-established healthcare system, world-class research institutions, and high patient demand for innovative treatments. The country is home to major biotech firms and academic centers leading clinical trials in cardiac regeneration. Europe: Europe is a key player in the cardiac tissue engineering market, supported by strong academic research, growing healthcare investments, and progressive regulatory frameworks. Countries like Germany, the UK, and the Netherlands are at the forefront of regenerative medicine innovation. Collaborative projects across universities, hospitals, and biotech firms drive the development of tissue-engineered heart valves, grafts, and myocardial patches. The European Medicines Agency (EMA) provides structured pathways for approval, enhancing clinical translation. With an aging population and a high incidence of cardiovascular conditions, Europe's demand for effective, regenerative cardiac therapies continues to rise, fostering steady market expansion across the region. Asia-Pacific: The Asia-Pacific region presents immense growth potential in the cardiac tissue engineering market due to its large patient population, rising cardiovascular disease burden, and increasing healthcare expenditure. Countries like China, Japan, South Korea, and India are investing heavily in biotechnology and regenerative medicine research. Government initiatives, growing collaborations with global players, and an expanding network of research institutions are driving innovation in the field. Additionally, lower clinical trial costs and favorable demographic trends are attracting companies to conduct studies and expand their footprint in the region. The rapid adoption of advanced medical technologies positions Asia-Pacific as a growing market hub. LAMEA: The LAMEA (Latin America, Middle East, and Africa) region is an emerging market for cardiac tissue engineering, with gradual improvements in healthcare infrastructure and growing awareness of regenerative therapies. Countries like Brazil, South Africa, and the UAE are beginning to invest in advanced medical research and adopt innovative treatment modalities. While market penetration is still in its early stages, increasing incidences of heart disease and collaborations with international research organizations are paving the way for development. Despite challenges like limited funding and regulatory barriers, the region shows long-term potential as local governments and institutions prioritize cardiovascular health. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detailed Information: support@ Browse the full 'Cardiac Tissue Engineering Market Size, Trends and Insights By Material (Scaffold, Stem Cells), By Product (Heart Valve, Vascular Grafts), By Application (MI, Congenital Heart Disease), By Distribution Channel (Hospitals & Clinics, Academics & Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Cardiac Tissue Engineering Market: Abbott Laboratories Artivion Inc. Athersys Inc. Baxter Internatioal Inc. Cellular Logistics Inc. Elutia Inc. Heartseed Inc. Medtronic Plc Merck kGaA Mesoblast Ltd. Neoolife Inc. Tejiin Limited Terumo Corporation L. Gore & Associates Inc. Others Click Here to Access a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: CRISPR and Cas Genes Market: CRISPR and Cas Genes Market Size, Trends and Insights By Technology Type (CRISPR/Cas9, CRISPR/Cas13, CRISPR/Cas14, Others), By Delivery Method (Ex vivo, In vivo, Physical Methods, Others), By Application Area (Functional Genomics, Oncology, Infectious Diseases, Others), By Tool Type (Guide RNA, CRISPR Plasmids, Cas Nucleases, Custom CRISPR Libraries, Vectors & Cloning Kits), By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Industrial Crops), By Disease Type (Cancer, Blood Disorders, Ophthalmic Diseases, Infectious Diseases, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Y Chromosome Microdeletion Detection Kit Market: Y Chromosome Microdeletion Detection Kit Market Size, Trends and Insights By Product Type (PCR-based Kits, FISH-based Kits, Others), By Application (Hospitals, Diagnostic Laboratories, Research Institutes, Others), By End-User (Healthcare Providers, Research Laboratories, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 CRISPR Gene Editing Market: CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and Reagents, Services), By Gene Editing Modality (Ex-Vivo Editing, In-Vivo Editing), By Technology (CRISPR/Cas9 Technology, CRISPR/Cas12 Technology, Prime Editing, Epigenetic Editing, Others), By Application (Therapeutic Applications, Agriculture and Livestock, Industrial Biotechnology), By End User (Biotechnology and Pharmaceutical Companies, Agricultural and Livestock Industry, Hospitals and Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Pneumothorax Treatment Market: Pneumothorax Treatment Market Size, Trends and Insights By Type (Primary Spontaneous, Secondary Spontaneous, Latrogenic, Injury Related, Catamenial), By Treatment (Medication, Antibiotics, Benzodiazepines, Opiate anesthetics, Others), By Diagnosis (Chest X-ray, Computerized Tomography Scan, Ultrasound, Physical Examination), By End-User (Hospitals, Clinics, Ambulatory Distribution Channel), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 VATS Instruments Market: VATS Instruments Market Size, Trends and Insights By Type (Forceps, Scissors, Clamps, Needle Holders, Others), By Application (Hospital, Clinic, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Japan Tissue Engineering Market: Japan Tissue Engineering Market Size, Trends and Insights By Type (Synthetic Scaffold Material, Biologically Derived Scaffold Material, Others), By Application (Orthopedics and Musculoskeletal, Neurology, Cardiovascular, Skin and Integumentary, Dental, Others), By End user (Hospitals and Clinics, Ambulatory Facilities), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Inferior Vena Cava IVC Filter Market: Inferior Vena Cava IVC Filter Market Size, Trends and Insights By Product Type (Retrievable Inferior Vena Cava filters, Permanent Inferior Vena Cava Filters), By Material (Non-Ferromagnetic Material, Ferromagnetic Materials), By Application (Treatment of Venous Thromboembolism, Prevention of Pulmonary Embolism), By End Users (Hospitals, Ambulatory Surgical Centers, Emergency Care Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Plant Tissue Culture Market: Plant Tissue Culture Market Size, Trends and Insights By Crop Type (Banana Plants, Floriculture Plants, Wood Producing Plants, Fruit Plants, Vegetable Plants, Ornamental Plants, Aquatic Plants, Others), By Stage (Explant preparation and Inoculation, Multiplication, Hardening), By Plant Type (Annual Plants, Biennial Plants, Perennial Plants), By Type of Media (Murashige and Skoog Media, Linsmaier and Skoog Media, Others), By Type of Growth Container (Test Tubes and Petri Dishes, Glass Bottles, Plastic Containers), By Application (Agriculture, Research, Gardening and Decoration, Forestry and Botanical Garden), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Cardiac Tissue Engineering Market is segmented as follows: By Material Scaffold Stem Cells By Product Heart Valve Vascular Grafts By Application MI Congenital Heart Disease By Distribution Channel Hospitals & Clinics Academics & Research Institutes Click Here to Get a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Cardiac Tissue Engineering Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Cardiac Tissue Engineering Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Cardiac Tissue Engineering Market? What Was the Capacity, Production Value, Cost and PROFIT of the Cardiac Tissue Engineering Market? What Is the Current Market Status of the Cardiac Tissue Engineering Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Cardiac Tissue Engineering Market by Considering Applications and Types? What Are Projections of the Global Cardiac Tissue Engineering Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Cardiac Tissue Engineering Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Cardiac Tissue Engineering Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Cardiac Tissue Engineering Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Cardiac Tissue Engineering Industry? Click Here to Access a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Reasons to Purchase Cardiac Tissue Engineering Market Report Cardiac Tissue Engineering Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Cardiac Tissue Engineering Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Cardiac Tissue Engineering Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Cardiac Tissue Engineering Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Cardiac Tissue Engineering market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Cardiac Tissue Engineering Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Cardiac Tissue Engineering market analysis. The competitive environment of current and potential participants in the Cardiac Tissue Engineering market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Cardiac Tissue Engineering market should find this report useful. The research will be useful to all market participants in the Cardiac Tissue Engineering industry. Managers in the Cardiac Tissue Engineering sector are interested in publishing up-to-date and projected data about the worldwide Cardiac Tissue Engineering market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Cardiac Tissue Engineering products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Cardiac Tissue Engineering Research Report | Fast Delivery Available - [220+ Pages] @
Globe and Mail
11 hours ago
- Business
- Globe and Mail
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why. The stock price came under pressure in July because the Q3 guidance update wasn't better than what the market expected. Sound crazy, but it's true: the robust outlook wasn't enough to keep speculators interested, but it isn't the speculators that matter in the long term. What matters in the long term is that the company's growth trajectory is positive, supporting a robust capital outlook that includes dividends and share repurchases. The combination of business growth, dividend distribution growth, and share repurchases serves as a lever for shareholder value that will propel the stock price to new highs. And the capital return is significant. The dividend is worth approximately 1.8% as of mid-July, is less than 50% of the earnings outlook, and has grown at a robust 10% CAGR over the past few years. Those are robust metrics for a Dividend Aristocrat, especially for a Dividend King like Abbott, which has increased its payout for over 50 years. That is a testament to management's foresight and execution, qualities that will continue to benefit investors in the long term. Abbott's share repurchases are also significant, as they reduce the share count quarterly. The company reduced its share count incrementally in the first half of the year and is expected to continue reducing it through the end of the year. Abbott Punished for Good Results, Solid Guidance Abbott Laboratories had a solid quarter, with revenue growth topping 7.4%, reported, about 70 basis points better than expected, driven by strength in all regions and reporting segments. Organically, growth was reported at 6.9% and 7.5% excluding COVID-19 testing supplies. Regionally, the U.S. was strongest at 8.7%, but the International Market was also solid at 6.6%. Segmentally, Diagnostics was the only weak point but was impacted by COVID, declining on a reported basis but rising incrementally organically. Other segments grew by at least 3%, led by a strong, industry-leading 12% gain in Medical Devices. The margin news is also good. Revenue leverage and operational quality offset macroeconomic pressures, resulting in a 100-basis-point improvement in adjusted gross and operating margins. The net result is $1.26 in adjusted earnings, only as expected, but up a leveraged 10.5% compared to the slower 7.4% top-line growth. The critical takeaway is that the cash flow is sufficient to sustain the capital return outlook, balance sheet health, and pipeline advancement, which support the stock price action over time. Regarding the pipeline, the company reported advancement of several key studies and one major approval for the quarter. Guidance is the sticking point for market action in July. The company narrowed its revenue growth range, indicating solid growth of 7.5% to 8%, with earnings in line with the consensus figure. However, a stronger catalyst was needed to lift the share prices. Investors should focus on growth, earnings, cash flow, and the pipeline, which promises to sustain them all. Analysts' Trends Provide Support for Abbott Laboratories in 2025 The analysts' trends are supportive of Abbott's stock price. The group issued a steady string of upgrades and price target revisions up to the day of the release, resulting in increasing coverage, firming sentiment, and a rising consensus price target. The group has the stock pegged at Moderate Buy with a bullish bias, forecasting a 10% increase relative to the pre-release closing price. That is sufficient to put this market at a new all-time high when reached. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
Yahoo
14 hours ago
- Business
- Yahoo
Abbott Laboratories (ABT): I Am Very Upset With Abbott,' Says Jim Cramer
We recently published . Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed. Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer's top stocks for most of this year, this show saw the CNBC TV host take a different tone. Abbott Laboratories (NYSE:ABT)'s shares fell by 8.5% in July after the firm's latest earnings results saw it warn about a massive $1 billion hit in 2025 from tariffs. Here's what Cramer said about the firm: 'I am very upset with Abbott. They're on tonight. I have supported the company for years and years. It's the diagnostic business. We'll have Robert Ford on tonight, it's not catastrophic because I like the company, long term. But, this is not, this was another thing that happened this morning that I found quite disturbing. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Previously, Cramer discussed Abbott Laboratories (NYSE:ABT)'s earnings before the release: 'Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative way during the earnings season. Abbott's a textbook example. It bothers me, but there are always sellers who claim to be disappointed. So, if you don't own any Abbott, may I suggest that you wait to see the numbers, wait for the stock's opening, wait for the sellers to appear. Patience is a virtue with ABT.' While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Intuitive Surgical (ISRG) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be announcing earnings results this Tuesday after market hours. Here's what to look for. Intuitive Surgical beat analysts' revenue expectations by 3.1% last quarter, reporting revenues of $2.25 billion, up 19.2% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts' EPS estimates but a miss of analysts' sales volume estimates. Is Intuitive Surgical a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Intuitive Surgical's revenue to grow 17.1% year on year to $2.35 billion, improving from the 14.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.92 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Intuitive Surgical has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.6% on average. Looking at Intuitive Surgical's peers in the healthcare equipment and supplies segment, only Abbott Laboratories has reported results so far. It beat analysts' revenue estimates by 0.9%, delivering year-on-year sales growth of 7.4%. The stock was down 6.1% on the results. Read our full analysis of Abbott Laboratories's earnings results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.3% on average over the last month. Intuitive Surgical's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $581.45 (compared to the current share price of $519). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
2 days ago
- Business
- Yahoo
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts
Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent years, Abbott Laboratories (NYSE:ABT)'s diabetes care division has emerged as its strongest growth engine, thanks largely to its continuous glucose monitoring (CGM) product line, FreeStyle Libre. According to the company, FreeStyle Libre has achieved record-breaking dollar sales, making it the most successful medical device in history. Despite this milestone, significant room for growth remains, as a large number of diabetics worldwide have yet to adopt CGM technology, despite its clear benefits. In addition, Abbott Laboratories (NYSE:ABT) holds the status of a Dividend King with 53 consecutive years of dividend growth under its belt. The company has grown its dividend payouts by nearly 146% over the past ten years. With a business model designed for durability, the company is seen as a reliable option for investors seeking steady dividend growth in the years ahead. It currently offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.95%, as of July 17. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
